FoundationOne Liquid CDx Identifies Patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer (mCRPC) who may be appropriate for treatment with Lynparza.
Read More
The handheld device works much like blood sugar monitors and can be used at home to measure a biomarker for cancer.
Read More
FDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Read More
The study demonstrates differential glycoproteomic profiles among covid-19-symptomatic and asymptomatic patients.
Read More
Foundation Medicine’s FoundationOne Liquid CDx is a pan-tumor liquid biopsy test for patients with solid tumors.
Read More